Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 16/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23270487 | 0.91 | NT5E (0.45) | NT5E | |
| SCHEMBL31078585 | 0.91 | NT5E (0.45) | NT5E | |
| SCHEMBL31078341 | 0.91 | NT5E (0.45) | NT5E | |
| SCHEMBL23270496 | 0.91 | NT5E (0.45) | NT5E | |
| SCHEMBL31078178 | 0.91 | NT5E (0.35) | NT5EADORA3ADORA1ADORA2A | |
| SCHEMBL23270580 | 0.89 | NT5E (0.33) | NT5EADORA3ADORA1ADORA2A | |
| SCHEMBL31622317 | 0.89 | NT5E (0.33) | NT5EADORA3ADORA1ADORA2A | |
| SCHEMBL31078191 | 0.89 | NT5E (0.33) | NT5EADORA3ADORA1ADORA2A | |
| SCHEMBL31078439 | 0.88 | NT5E (0.46) | NT5E | |
| SCHEMBL31078334 | 0.88 | NT5E (0.46) | NT5EADORA3ADORA1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331068-B2 | Compositions and methods for inhibiting CD73 | PELOTON THERAPEUTICS, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| EP-3810109-B1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING CD73 | PELOTON THERAPEUTICS INC (US) | 2024-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12331068-B2 | Compositions and methods for inhibiting CD73 | ENTPD5, NT5E, ENTPD1 | NT5E 2/4885ADORA3 27/4885ADORA1 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.